01.11.2012 • NewsAcronfertilizerfertiliser

Russia's Acron Agrees $1.5 Billion Potash Project Financing

Russia's Acron, one of Europe's top 10 mineral fertilizer makers, has agreed $1.5 billion of equity and debt financing for a potash project in Russia, which could boost its output in four years.

Acron has attracted Russian state bank Vnesheconombank (VEB), Eurasian Development Bank and Raiffeisenbank to finance construction of its Talitsky mine in Russia's Urals region, which aims to start potash production in 2016, the company said on Thursday.

In a first stage, the three banks have acquired equity in Acron's firm which operates the project for 12.8 billion roubles ($408 million).

VEB bought 20% minus one share, Eurasian Development Bank received 9.1% and Raiffeisenbank received 8.95%. Acron owns the remaining share of the project.

These investments will allow full-scale construction of the Talitsky mine to start in the fourth quarter of 2012. The total capital expenditure required for the project is estimated at $2 billion, excluding the cost of the mining licence for the Talitsky area, which was about $700 million.

In the second part of the deal, VEB will provide debt financing in the form of a $1.1 billion credit line facility for further development of the project in 2014.

 

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.